scholarly journals Diagnosis of infection by SARS-COV-2: Is one molecular test enough?

Author(s):  
Antonella Mencacci ◽  
Maria Cristina Vedovati ◽  
Barbara Camilloni ◽  
Elio Cenci ◽  
Cecilia Becattini
2018 ◽  
Vol 12 (2) ◽  
pp. 75-84
Author(s):  
M.V. Arisov ◽  
I.P. Belykh ◽  
V.V. Artemov

The purpose of the research: the study of the efficacy of the preparations for veterinary use "Inspector Quadro C" and "Inspector Quadro K" against ecto- and endoparasitoses of dogs and cats. Materials and methods. Studies were conducted on spontaneously infected dogs and cats of different sexes, age, weight and breed. The diagnosis of infection with ectoparasites was made based on the clinical picture and laboratory methods of investigation (microscopy of scrapings taken from ectoparasitized skin areas, examination of the coat for fleas, lice, worms, ixodids). Infection with helminths was established by detecting eggs of helminths in faeces of animals by the method of Füleleborn and mature segments of cestodes. Preparations were applied to the animals by drip application on dry undamaged skin in places inaccessible to licking in a dose of 0.1-0.4 ml per 1 kg of body weight. The results were statistically processed. Results and discussion. "Inspector Quadro S" and "Inspector Quadro K" showed 100% efficacy at sarcoptosis in dogs, notoedrosis in cats, otodectosis in dogs and cats, ixodidoses and entomoses. "Inspector Quadro C" showed a high efficiency (92.3%) at demodecosis in dogs. However, single mites were found in one dog. 100% efficacy of "Inspector Quadro C" and "Inspector Quadro K" has been established against intestinal nematodes and cestodes in dogs and cats. Negative effects of drugs on the body of animals have not been revealed.


2019 ◽  
Author(s):  
Shahid Habib ◽  
Nehali Patel ◽  
Sandeep Yarlagadda ◽  
Sarah N. Patel ◽  
Lindsey M. Schader ◽  
...  

2017 ◽  
Vol 42 ◽  
pp. 413
Author(s):  
Bruno Gonçalves Silva ◽  
Ricardo Turon Costa da Silva ◽  
Daniel Ferreira de Barros Rodrigues ◽  
Nivea Melo ◽  
Fabio Guimaraes de Miranda ◽  
...  

Author(s):  
Mattia Loppini ◽  
Alessandro Pisano ◽  
Marco Di Maio ◽  
Francesco La Camera ◽  
Maddalena Casana ◽  
...  

Author(s):  
J Stephen Nix ◽  
Cristiane M Ida

Abstract Molecular testing has become part of the routine diagnostic workup of brain tumors after the implementation of integrated histomolecular diagnoses in the 2016 WHO classification update. It is important for every neuropathologist to be aware of practical preanalytical, analytical, and postanalytical factors that impact the performance and interpretation of molecular tests. Prior to testing, optimizing tumor purity and tumor amount increases the ability of the molecular test to detect the genetic alteration of interest. Recognizing basic molecular testing platform analytical characteristics allows selection of the optimal platform for each clinicopathological scenario. Finally, postanalytical considerations to properly interpret molecular test results include understanding the clinical significance of the detected genetic alteration, recognizing that detected clinically significant genetic alterations are occasionally germline constitutional rather than somatic tumor-specific, and being cognizant that recommended and commonly used genetic nomenclature may differ. Potential pitfalls in brain tumor molecular diagnosis are also discussed.


Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 436
Author(s):  
Monika Maria Biernat ◽  
Anna Kolasińska ◽  
Jacek Kwiatkowski ◽  
Donata Urbaniak-Kujda ◽  
Paweł Biernat ◽  
...  

The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48–72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma–treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies.


Author(s):  
Marco Ciotti ◽  
Eleonora Nicolai ◽  
Fabbio Marcuccilli ◽  
Sergio Bernardini
Keyword(s):  

2021 ◽  
pp. 100076
Author(s):  
Josiah Levi Davidson ◽  
Jiangshan Wang ◽  
Murali Kannan Maruthamuthu ◽  
Andres Dextre ◽  
Ana Pascual-Garrigos ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document